» Articles » PMID: 316435

Acquired Von Willebrand's Syndrome with IgM Inhibitor Against Von Willebrand's Factor

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1979 Oct 1
PMID 316435
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This report describes a patient without evident underlying disease, in whom an acquired von Willebrand's syndrome was discovered before surgery. Coagulation abnormalities included a borderline bleeding time, a low retention of platelets on glass beads, decreased levels of factor VIII procoagulant activity (VIIIAHF), factor VIII-related antigen (VIIIAg), and ristocetin-induced agglutination cofactor (VIIIVWF). After cryoprecipitate infusion the patient did not have the expected rise and there was no secondary increment in VIIIAHF. The patient was treated with prednisone for three weeks without significant improvement in the laboratory findings. Spontaneous resolution was observed long after this therapy. The haemostatic abnormalities were attributable to the presence of an inhibitor directed against VIIIVWF. The inhibitor was found in the IgM fraction. Its autoimmune nature is probable although we failed to demonstrate any inhibitory effect of Fab obtained from the patient's purified IgM. Despite the lack of inhibitory effect against VIIIAHF and VIIIAg, the low levels of all three activities of the factor VIII complex could be explained by the short half-life of immune complexes between factor VIII and the inhibitor.

Citing Articles

Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production.

York E, Dratch B, Ito J, Horwitz S, Emamian S, Ambarian J J Thromb Haemost. 2024; 23(2):440-457.

PMID: 39476969 PMC: 11786990. DOI: 10.1016/j.jtha.2024.10.017.


Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Mohri H J Thromb Thrombolysis. 2004; 15(3):141-9.

PMID: 14739623 DOI: 10.1023/B:THRO.0000011369.70824.e6.


Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone.

Stewart A, GLYNN M Postgrad Med J. 1990; 66(777):560-2.

PMID: 2120689 PMC: 2429624. DOI: 10.1136/pgmj.66.777.560.

References
1.
Gazengel C, Prieur A, Jacques C, Buriot D, Nedellec J, JOSSO F . Antibody-induced von Willebrand syndrome: inhibition of VIII VWF and VIII AGN with sparing of VIII AHF by the autoantibody. Am J Hematol. 1978; 5(4):355-63. DOI: 10.1002/ajh.2830050411. View

2.
Stableforth P, Tamagnini G, DORMANDY K . Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation. Br J Haematol. 1976; 33(4):565-73. DOI: 10.1111/j.1365-2141.1976.tb03575.x. View

3.
Rosborough T, Swaim W . Acquired von Willebrand's disease, platelet-release defect and angiodysplasia. Am J Med. 1978; 65(1):96-100. DOI: 10.1016/0002-9343(78)90698-8. View

4.
Joist J, Cowan J, ZIMMERMAN T . Acquired von Willebrand's disease. Evidence for a quantitative and qualitative factor VIII disorder. N Engl J Med. 1978; 298(18):988-91. DOI: 10.1056/NEJM197805042981802. View

5.
Chediak J, Telfer M, Green D . Platelet function and immunologic parameters in von Willebrand's disease following cryoprecipitate and factor VIII concentrate infusion. Am J Med. 1977; 62(3):369-76. DOI: 10.1016/0002-9343(77)90834-8. View